Short answer
Annexon, Inc. (ANNX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$51M
- +6.7% YoY · +7.5% QoQ
- EPS (diluted)
- −$0.25
- +32.4% YoY · +7.4% QoQ
Source: XBRL data from the Annexon, Inc. (ANNX) Q3 2026 10-Q on SEC EDGAR. USD.
Annexon, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; quarterly net loss $51.2M vs $54.9M YoY, down 7%
- R&D expenses $41.4M vs $49.7M YoY, down 17%, driven by lower contract manufacturing
- G&A expenses $10.9M vs $7.3M YoY, up 49%, worst cost trend versus R&D
- Cash and investments $213.4M; operating cash use $143.5M through nine months vs $140.4M YoY
- $50.0M term loan funded; cash runway into 2028, with substantial additional financing required
Risk Factors
- New financing risk: July 2026 Loan Agreement added $50.0 million debt, with floating interest of at least 7.60% and substantially all assets pledged
- Most material clinical update: ARCHER II expanded in August 2026 with Month 24 dual primary endpoint and open-label extension, increasing duration, complexity and funding needs
- Regulatory risk: FDA indicated tanruprubart’s foreign-data generalizability package may require additional GBS patient data before BLA approval
- Competitive risk: Two approved GA products may limit vonaprument adoption if it reaches commercialization
- Liquidity risk: $213.4 million in cash and short-term investments expected to fund operations into 2028, but expanded Phase 3 work may require earlier financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Annexon, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.